comparemela.com

Latest Breaking News On - Otsuka lundbeck - Page 1 : comparemela.com

Is a Victory for Its Rivals Bad News for Axsome Therapeutics?

FDA approves supplemental new drug application for Rexulti

The FDA has approved a supplemental new drug application for Rexulti for the treatment of agitation associated with dementia due to Alzheimer’s disease.According to a joint press release from Otsuka and Lundbeck, the approval makes Rexulti (brexpiprazole, Otsuka/Lundbeck) the first and only treatment approved in the United States for this common neuropsychiatric symptom of AD, which is

Frontiers | Editorial: Outbreak Investigation: Mental Health in the Times of Coronavirus (COVID-19)

Vitamin D supplementation not tied to mental health outcomes in first-episode psychosis

Vitamin D supplementation did not appear linked to mental health or metabolic outcomes at 6 months in people with first-episode psychosis, according to results of a randomized clinical trial published in JAMA Network Open. “We report the results of the DFEND (Vitamin D Supplementation Compared to Placebo in People With First Episode Psychosis–Neuroprotection Design) trial,”

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.